ImmunoGen Company Profile (NASDAQ:IMGN)

About ImmunoGen

ImmunoGen logoImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IMGN
  • CUSIP: 45253H10
Key Metrics:
  • Previous Close: $2.71
  • 50 Day Moving Average: $2.44
  • 200 Day Moving Average: $2.37
  • 52-Week Range: $1.51 - $9.78
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.94
  • P/E Growth: 0.00
  • Market Cap: $237.31M
  • Outstanding Shares: 87,301,000
  • Beta: 1.98
  • Net Margins: -292.83%
  • Return on Assets: -60.67%
  • Debt-to-Equity Ratio: -0.79%
  • Current Ratio: 3.69%
  • Quick Ratio: 3.65%
Additional Links:
Companies Related to ImmunoGen:

Analyst Ratings

Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $6.28 (131.65% upside)

Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
DateFirmActionRatingPrice TargetDetails
2/18/2017Canaccord GenuitySet Price TargetBuy$6.00View Rating Details
2/18/2017RBC Capital MarketsSet Price TargetHold$3.00View Rating Details
10/30/2016Cantor FitzgeraldSet Price TargetHold$5.00View Rating Details
8/5/2016Jefferies Group LLCReiterated RatingBuy$13.00 -> $6.00View Rating Details
8/5/2016J P Morgan Chase & CoSet Price TargetHold$9.00 -> $5.00View Rating Details
6/6/2016Cowen and CompanyReiterated RatingHoldView Rating Details
5/19/2016Royal Bank of CanadaReiterated RatingSector Perform$7.00View Rating Details
5/5/2016Morgan StanleyReiterated RatingUnderweight$9.00 -> $5.00View Rating Details
5/2/2016Leerink SwannBoost Price TargetMarket Perform$8.00 -> $11.00View Rating Details
1/31/2016William BlairReiterated RatingOutperformView Rating Details
11/10/2015Oppenheimer Holdings, Inc.Reiterated RatingBuy$24.00View Rating Details
5/6/2015Credit Suisse GroupInitiated CoverageNeutral$10.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for ImmunoGen (NASDAQ:IMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/17/2017Q2 2017($0.38)($0.39)$16.28 million$13.85 millionViewListenView Earnings Details
10/28/2016Q117($0.38)($0.51)$21.12 million$7.66 millionViewListenView Earnings Details
8/4/2016Q416($0.39)($0.51)$17.11 million$7.41 millionViewListenView Earnings Details
4/29/2016Q316($0.31)($0.37)$23.02 million$19.71 millionViewListenView Earnings Details
1/29/2016Q216($0.36)($0.38)$17.87 millionViewListenView Earnings Details
10/27/2015Q116($0.35)($0.39)$15.84 million$14.90 millionViewListenView Earnings Details
7/31/2015Q415($0.34)($0.35)$15.42 million$12.61 millionViewListenView Earnings Details
4/24/2015Q315($0.25)($0.25)$20.95 million$11.40 millionViewListenView Earnings Details
1/30/2015Q215($0.04)$0.16$37.30 million$48.30 millionViewListenView Earnings Details
10/24/2014Q115($0.15)($0.26)$21.80 million$13.20 millionViewListenView Earnings Details
8/1/2014Q414($0.32)($0.83)$9.72 million$5.74 millionViewN/AView Earnings Details
4/25/2014Q314($0.27)($0.44)$13.28 million$6.90 millionViewN/AView Earnings Details
1/31/2014Q214($0.18)($0.29)$18.16 million$30.10 millionViewListenView Earnings Details
10/25/2013Q114($0.23)($0.13)$12.10 million$17.20 millionViewN/AView Earnings Details
8/2/2013Q4 2013($0.30)($0.26)$3.44 million$3.83 millionViewN/AView Earnings Details
4/26/2013Q3 2013($0.15)($0.02)$11.94 million$25.00 millionViewN/AView Earnings Details
1/25/2013Q2 2013($0.25)($0.29)$6.02 million$2.60 millionViewN/AView Earnings Details
10/26/2012Q113($0.25)($0.30)$4.10 million$4.10 millionViewN/AView Earnings Details
8/3/2012($0.30)($0.29)ViewN/AView Earnings Details
4/27/2012($0.26)($0.24)ViewN/AView Earnings Details
1/27/2012($0.22)($0.17)ViewN/AView Earnings Details
10/27/2011($0.22)($0.26)ViewN/AView Earnings Details
8/3/2011($0.24)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ImmunoGen (NASDAQ:IMGN)
Current Year EPS Consensus Estimate: $-1.40 EPS
Next Year EPS Consensus Estimate: $-1.40 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.38)($0.38)($0.38)
Q2 20163($0.38)($0.36)($0.37)
Q4 20161($0.42)($0.42)($0.42)
Q3 20171($0.39)($0.39)($0.39)
Q4 20171($0.40)($0.40)($0.40)
Q1 20181($0.43)($0.43)($0.43)
Q2 20181($0.43)($0.43)($0.43)
Q3 20181($0.43)($0.43)($0.43)
Q4 20181($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)


Dividend History for ImmunoGen (NASDAQ:IMGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ImmunoGen (NASDAQ:IMGN)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 85.26%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Mark Alan GoldbergDirectorBuy20,000$1.80$36,000.00View SEC Filing  
11/8/2016Mark J EnyedyCEOBuy25,000$1.83$45,750.00View SEC Filing  
11/2/2016Craig BarrowsInsiderBuy10,000$1.71$17,100.00View SEC Filing  
11/2/2016Richard J GregoryVPBuy16,600$1.78$29,548.00View SEC Filing  
2/1/2016John LambertEVPSell3,889$8.22$31,967.58View SEC Filing  
1/8/2016Richard J GregoryVPSell2,369$11.10$26,295.90View SEC Filing  
1/4/2016Daniel M. JuniusCEOSell5,416$13.17$71,328.72View SEC Filing  
1/4/2016John LambertEVPSell3,889$13.20$51,334.80View SEC Filing  
12/1/2015Daniel M. JuniusCEOSell5,416$13.11$71,003.76View SEC Filing  
12/1/2015John LambertEVPSell3,889$13.11$50,984.79View SEC Filing  
11/27/2015Charles Q MorrisVPSell5,170$14.00$72,380.00View SEC Filing  
11/17/2015Dean J MitchellDirectorBuy10,000$12.51$125,100.00View SEC Filing  
11/2/2015Daniel M. JuniusCEOSell5,497$12.00$65,964.00View SEC Filing  
11/2/2015John LambertEVPSell3,889$11.73$45,617.97View SEC Filing  
10/29/2015Daniel M. JuniusCEOSell5,335$12.01$64,073.35View SEC Filing  
10/1/2015John LambertEVPSell3,889$9.55$37,139.95View SEC Filing  
9/17/2015David Brannon JohnstonCFOSell5,000$15.00$75,000.00View SEC Filing  
9/1/2015Daniel M. JuniusCEOSell5,416$13.15$71,220.40View SEC Filing  
9/1/2015John LambertEVPSell3,889$13.16$51,179.24View SEC Filing  
7/1/2015Daniel M JuniusCEOSell5,416$14.34$77,665.44View SEC Filing  
7/1/2015John LambertEVPSell3,888$14.34$55,753.92View SEC Filing  
6/15/2015Nicole OnettoDirectorSell3,211$13.86$44,504.46View SEC Filing  
6/1/2015John LambertEVPSell15,000$11.78$176,700.00View SEC Filing  
5/7/2015Daniel M JuniusCEOSell1,215$8.02$9,744.30View SEC Filing  
5/1/2015John LambertEVPSell10,000$8.32$83,200.00View SEC Filing  
11/28/2014Charles Q MorrisVPSell5,240$10.40$54,496.00View SEC Filing  
3/17/2014Daniel JuniusCEOSell15,000$16.40$246,000.00View SEC Filing  
2/26/2014Charles MorrisVPSell6,936$17.35$120,339.60View SEC Filing  
2/20/2014Charles MorrisVPSell13,672$17.10$233,791.20View SEC Filing  
2/18/2014Daniel JuniusCEOSell15,000$16.26$243,900.00View SEC Filing  
2/3/2014John LambertEVPSell4,375$14.90$65,187.50View SEC Filing  
1/22/2014Charles MorrisVPSell7,138$17.00$121,346.00View SEC Filing  
1/10/2014Theresa WingroveVPSell6,250$15.04$94,000.00View SEC Filing  
1/2/2014John LambertEVPSell4,375$14.53$63,568.75View SEC Filing  
12/10/2013Daniel JuniusCEOSell15,000$15.11$226,650.00View SEC Filing  
12/2/2013John LambertEVPSell4,375$14.70$64,312.50View SEC Filing  
11/26/2013Charles MorrisVPSell12,500$13.75$171,875.00View SEC Filing  
11/1/2013John LambertEVPSell4,375$16.41$71,793.75View SEC Filing  
9/10/2013Gregory D PerryCFOSell18,337$17.82$326,765.34View SEC Filing  
9/3/2013Daniel JuniusCEOSell16,667$16.43$273,838.81View SEC Filing  
9/3/2013John LambertEVPSell4,375$16.45$71,968.75View SEC Filing  
8/1/2013Daniel M JuniusCEOSell16,667$19.21$320,173.07View SEC Filing  
8/1/2013John LambertEVPSell4,375$19.21$84,043.75View SEC Filing  
7/11/2013James J O'learyVPSell35,000$19.02$665,700.00View SEC Filing  
7/3/2013Daniel M JuniusCEOSell16,667$17.31$288,505.77View SEC Filing  
7/1/2013John LambertEVPSell4,375$16.80$73,500.00View SEC Filing  
6/3/2013John LambertEVPSell11,250$17.20$193,500.00View SEC Filing  
5/24/2013James J O'learyVPSell28,900$18.11$523,379.00View SEC Filing  
5/1/2013John LambertEVPSell11,250$15.56$175,050.00View SEC Filing  
4/11/2013James J O'learyVPSell31,100$17.37$540,207.00View SEC Filing  
11/8/2012Mark Alan GoldbergDirectorBuy3,000$11.27$33,810.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for ImmunoGen (NASDAQ:IMGN)
DateHeadline logoImmunoGen : Technical Reports on Biotech Stocks -- Juno Therapeutics, Protalix BioTherapeutics, ImmunoGen, and ContraVir Pharma (NASDAQ:IMGN) - February 23 at 10:55 PM logoImmunoGen's 4Q Loss Wider Than Expected (IMGN) (NASDAQ:IMGN) - February 20 at 5:21 PM logoImmunoGen 4Q Loss Misses Street Expectations (NASDAQ:IMGN) - February 20 at 5:21 PM logoImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y (NASDAQ:IMGN) - February 20 at 10:38 AM logoImmunoGen : reports 2Q loss (NASDAQ:IMGN) - February 18 at 10:57 AM logoEdited Transcript of IMGN earnings conference call or presentation 17-Feb-17 1:00pm GMT (NASDAQ:IMGN) - February 18 at 10:57 AM logoIMMUNOGEN INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:IMGN) - February 17 at 5:31 PM logoImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016 (NASDAQ:IMGN) - February 17 at 5:31 PM logoImmunoGen reports 2Q loss (NASDAQ:IMGN) - February 17 at 5:31 PM logoIMMUNOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:IMGN) - February 17 at 5:31 PM logoQ2 2017 ImmunoGen Inc Earnings Release - 06:30 am ET (NASDAQ:IMGN) - February 17 at 5:31 PM logoImmunoGen Inc Earnings Call scheduled for 8:00 am ET today (NASDAQ:IMGN) - February 17 at 5:31 PM logoImmunoGen (IMGN) Reports Wider-than-Expected Loss (NASDAQ:IMGN) - February 17 at 5:31 PM
News IconImmunoGen, Inc. NASDAQ:IMGN Volatility at Extreme Levels - Aiken Advocate (NASDAQ:IMGN) - February 16 at 4:45 PM
News IconStock Perspective: ImmunoGen, Inc. (NASDAQ:IMGN) Earnings in View - Aiken Advocate (NASDAQ:IMGN) - February 15 at 9:02 PM logoWhat's in Store for ImmunoGen (IMGN) this Earnings Season? (NASDAQ:IMGN) - February 13 at 11:14 AM
News IconForward Earnings Estimate of ImmunoGen, Inc.(IMGN) - Highland Mirror (NASDAQ:IMGN) - February 12 at 4:01 AM
News IconInvestor Focus on Shares of ImmunoGen Inc. (IMGN) - Rives Journal (NASDAQ:IMGN) - February 8 at 5:15 AM
News IconImmunoGen Inc IMGN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:IMGN) - February 6 at 10:37 AM logoImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences (NASDAQ:IMGN) - February 2 at 6:36 PM
News IconIs Now the Time to Capitalize on ImmunoGen, Inc. (NASDAQ:IMGN) - Prospect Journal (NASDAQ:IMGN) - February 1 at 6:39 PM
News IconAre Insiders Bumping Up Their Positions in ImmunoGen, Inc. (NASDAQ:IMGN) - Wall Street Beacon (NASDAQ:IMGN) - February 1 at 5:30 AM
News IconNews Impact Score Of ImmunoGen, Inc. (NASDAQ:IMGN) At 83 - Stock Observer (NASDAQ:IMGN) - February 1 at 5:30 AM
News IconStock Review: Checking in on Share of ImmunoGen, Inc. (NASDAQ:IMGN) - Gilbert Daily (NASDAQ:IMGN) - January 29 at 6:05 PM
News IconStock on Trader's Radar: ImmunoGen, Inc. (NASDAQ:IMGN ... - The Newburgh Press (NASDAQ:IMGN) - January 27 at 7:50 PM logoImmunogen Doses First Patient in Ovarian Cancer Drug Study (NASDAQ:IMGN) - January 27 at 7:50 PM logoImmunogen (IMGN) Doses First Patient in FORWARD I Phase 3 Study of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer (NASDAQ:IMGN) - January 27 at 12:37 AM
News IconImmunoGen, Inc. (NASDAQ:IMGN) Quarterly Analytical Analysis - The Newburgh Press (NASDAQ:IMGN) - January 26 at 7:36 PM
News IconEarnings in Full Force, Analysts Take Aim at ImmunoGen, Inc. (NASDAQ:IMGN) - Wall Street Beacon (NASDAQ:IMGN) - January 26 at 7:36 PM logoImmunoGen Announces First Patient Dosed in FORWARD I Phase 3 Study of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer (NASDAQ:IMGN) - January 26 at 7:36 PM logoImmunoGen Announces Conference Call to Discuss its Results for Six-Month Period and Quarter Ended December 31 (NASDAQ:IMGN) - January 25 at 7:18 PM
News IconStock Backsliding Ahead of the Bell: ImmunoGen, Inc. (NASDAQ:IMGN) - Aiken Advocate (NASDAQ:IMGN) - January 23 at 11:10 PM logoIMMUNOGEN INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) (NASDAQ:IMGN) - January 23 at 6:10 PM logoImmunoGen Announces Departure of Sandra Poole (NASDAQ:IMGN) - January 23 at 6:10 PM logoIMMUNOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:IMGN) - January 23 at 6:10 PM
News IconPrepping for a Big Move? Share Update on ImmunoGen, Inc. (NASDAQ:IMGN) - Prospect Journal (NASDAQ:IMGN) - January 20 at 8:26 PM
News IconImmunoGen, Inc. (NASDAQ:IMGN):Brokerage Firm Rating Analysis - Highland Mirror (NASDAQ:IMGN) - January 19 at 7:41 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: ImmunoGen, Inc. (NASDAQ:IMGN) - Wall Street Beacon (NASDAQ:IMGN) - January 18 at 6:24 PM
News IconBiotech Mergers and Acquisitions Could See Significant Rebound (NASDAQ:IMGN) - January 16 at 5:51 PM
News IconWill The Needle Move For ImmunoGen, Inc. (NASDAQ:IMGN) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:IMGN) - January 12 at 11:23 PM
News IconAnalyst Issues Short Term Price Target on ImmunoGen, Inc. (NASDAQ:IMGN) - Highland Mirror (NASDAQ:IMGN) - January 12 at 11:23 PM logoIMMUNOGEN INC : Results of Operations and Financial Condition (form 8-K) (NASDAQ:IMGN) - January 12 at 6:22 PM logoShort Interest Declines 10.4% For IMGN (NASDAQ:IMGN) - January 12 at 6:22 PM logoIMMUNOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:IMGN) - January 12 at 6:22 PM
News IconNews Impact Score Of ImmunoGen, Inc. (NASDAQ:IMGN) Set At 83 - Stock Observer (NASDAQ:IMGN) - January 11 at 8:01 AM
News IconTraders Watch list: Nuance Communications, Inc. (NASDAQ:NUAN), ImmunoGen, Inc. (NASDAQ:IMGN) (NASDAQ:IMGN) - January 8 at 5:48 AM logoIMMUNOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IMGN) - January 4 at 6:47 PM logoLatest Reports on Stocks to Watch: Inotek Pharmaceuticals and ImmunoGen (NASDAQ:IMGN) - January 4 at 6:47 PM logoWhy ImmnoGen, Inc. Jumped Higher Today (NASDAQ:IMGN) - January 4 at 6:47 PM
News IconStock ready to Pivot? Focus on Shares of ImmunoGen, Inc. (NASDAQ:IMGN) - Prospect Journal (NASDAQ:IMGN) - January 4 at 2:02 AM


What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?

9 analysts have issued 12 month target prices for ImmunoGen's stock. Their forecasts range from $3.00 to $11.00. On average, they anticipate ImmunoGen's share price to reach $6.28 in the next year.

When will ImmunoGen announce their earnings?

ImmunoGen is scheduled to release their next quarterly earnings announcement on Thursday, April, 27th 2017.

Who owns ImmunoGen stock?

ImmunoGen's stock is owned by a number of of institutional and retail investors. Top institutional investors include PRIMECAP MANAGEMENT COMPANY Total Shares: 6,606,653 (7.57%), Orbimed Advisors LLC (6.98%), Renaissance Technologies LLC (2.84%), Pinnacle Associates Ltd. (1.86%), State Street Corp (1.75%) and FMR LLC (0.92%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, David Brannon Johnston, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy, Nicole Onetto and Richard J Gregory.

Who sold ImmunoGen stock? Who is selling ImmunoGen stock?

ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Pinnacle Associates Ltd., AQR Capital Management LLC, Renaissance Technologies LLC and Two Sigma Investments LP.

Who bought ImmunoGen stock? Who is buying ImmunoGen stock?

ImmunoGen's stock was acquired by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC, State Street Corp and Federated Investors Inc. PA. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory.

How do I buy ImmunoGen stock?

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ImmunoGen stock cost?

One share of ImmunoGen stock can currently be purchased for approximately $2.71.

ImmunoGen (NASDAQ:IMGN) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for ImmunoGen (NASDAQ:IMGN)

Earnings History Chart

Earnings by Quarter for ImmunoGen (NASDAQ:IMGN)

Dividend History Chart

Dividend Payments by Quarter for ImmunoGen (NASDAQ:IMGN)

Last Updated on 2/24/2017 by Staff